ABSTRACT
PURPOSE: The aim of this study was to investigate the efficacy of artemether-lumefantrine in treating uncomplicated Plasmodium falciparum malaria in four sentinel areas in Sudan with different malaria transmission (Damazin, Sinnar, and Kosti in the north, and Juba in the south). METHODS: World Health Organization protocol for assessing antimalarial drug efficacy in treating uncomplicated P. falciparum malaria was employed. A total of 2,139 patients were screened, and 771 had P. falciparum monoinfection. Only 291 met the enrollment criteria and gave written consent to be recruited in the study. Patients were treated with artemether-lumefantrine tablets in a six-dose regimen calculated according to body weight. Tablets were given at 0, 8, 24, 36, 48, and 60 h. Patients were followed up for 28 days. RESULTS: A total of 291 patients were recruited to the study, of whom ten [3.4; 95% confidence interval (CI):1.8-6.4%] patients showed early treatment failure (ETF) or late clinical failure (LCF) and were excluded from further follow-up. Of the remaining 281 patients, 276 (98.2%; 95% CI: 95.7-99.3%) completed the 28-day follow-up. Of these, 274 (99.3%; 95% CI: 97.1-99.9%) had adequate clinical and parasitological response (ACPR), and two (0.7%; 95% CI: 0.13-2.9%) showed late parasitological failure (LPF) at days 21 and 28. The overall mean +/- standard deviation (SD) of parasitemia and fever clearance times were 36.4 (23.7) h and 34.6 (19.2) h, respectively. Mild and reversible adverse effects were reported by 11 patients (3.8%; CI: 2.0- 7.0%) and were relieved without the need for termination of drug therapy or supportive treatment. CONCLUSIONS: Our findings showed that artemether-lumefantrine was an effective and safe drug for treating uncomplicated P. falciparum malaria in northern and southern Sudan.
Subject(s)
Antimalarials/therapeutic use , Artemisinins/therapeutic use , Ethanolamines/therapeutic use , Fluorenes/therapeutic use , Malaria, Falciparum/drug therapy , Administration, Oral , Adolescent , Adult , Antimalarials/administration & dosage , Antimalarials/adverse effects , Artemether, Lumefantrine Drug Combination , Artemisinins/adverse effects , Child , Child, Preschool , Drug Administration Schedule , Drug Combinations , Ethanolamines/adverse effects , Female , Fever/drug therapy , Fever/parasitology , Fluorenes/adverse effects , Humans , Infant , Infant, Newborn , Malaria, Falciparum/parasitology , Malaria, Falciparum/transmission , Male , Parasitemia/drug therapy , Sudan , Tablets , Time Factors , Treatment Outcome , Young AdultABSTRACT
OBJECTIVE: The aim of this study was to estimate the prevalence of self-medication with proprietary medicines and herbs in Khartoum State, Sudan, and to evaluate factors associated with self-medication. METHODS: A pre-piloted questionnaire was used to collect data from a sample of 1,200 individuals, selected from all three cities of Khartoum State using a multistage stratified clustered sampling. RESULTS: The response rate was 83.3%. Medicines, including herbs, were used by 81.8% of the respondents without a medical consultation within 2 months prior to the study period. Proprietary medicines alone were used by 28.3% (CI: 25.6-31.2), herbs alone by 20.7% (CI: 18.3-23.4), while 32.8% (CI: 29.9-35.8) had used both. Self-medication with proprietary medicines was least common with the middle-aged (OR: 0.12; 0.09-0.17), the elderly (OR: 0.29; 0.20-0.42) and low level of education [illiterate (OR: 0.26, 0.18-0.37) and primary/intermediate school (OR: 0.07, 0.04-0.11)]. It was most associated with low (OR: 5.3; 3.8-7.4) and middle income (OR: 4.3; 3.1-5.9), but no gender difference was found (P>0.05). Self-medication behaviour with herbs was most associated with middle-age (OR: 1.7; 1.3-2.2), female gender (OR: 2.2 (1.7-2.8) and lowest income earners (OR: 2.5; 1.9-3.5). CONCLUSIONS: The prevalence of self-medication with medicines including herbs in urban areas of Khartoum State is high. Self-medication behaviour varies significantly with a number of socio-economic characteristics. Our findings have major public health policy implications for countries like Sudan.
